Ultrasound therapy developer Theraclion has received an order for its Echopulse system from Helios Klinik Schkeuditz in Germany.
The Echopulse sale is the first to a private institution in Germany and the first in the eastern part of the country, according to Theraclion. Echopulse will now be in use at 11 institutions around the world, the company said.
In other Theraclion news, the vendor is directing attention to a recent study involving Echopulse that was published online on 24 November in Expert Review of Medical Devices. In a study of 10 female patients receiving treatment for breast fibroadenomas, researchers from Sapienza University of Rome found that ultrasound-guided high-intensity focused ultrasound (HIFU) offered a number of benefits over MR-guided HIFU, including shorter treatment time, more comfortable patient positioning, and avoidance of contrast agents before and after treatment, Theraclion said.
